Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Stock Climbs 7.4 Percent on Divestiture Announcement

NEW YORK, Oct. 7 (GenomeWeb News) - Shares in PerkinElmer were up 7.37 percent, or $.1.52, at $22.15 in mid-afternoon trading after the company said yesterday it is selling its aerospace, semiconductor, and fluid-testing businesses.

 

As GenomeWeb News reported this morning, the company said the divestitures are part of its strategy to shift its focus on the health sciences and photonic markets.

 

PE will sell its aerospace business to Eaton for approximately $333 million, and is in discussions to sell its semiconductor and fluid testing businesses by the end of the year. The company said it expects to gain approximately $400 million from the sale of the Fluid Sciences business alone.

 

The proceeds from the sales "will help us build our growth platforms, with particular emphasis on genetic screening, medical imaging, molecular medicine, and service," PE chairman and CEO Gregory Summe said in a company statement.

 

Separately today, investment bank R.W. Baird upgraded PerkinElmer to "outperform" from "neutral."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.